1. Home
  2. BILI vs PRAX Comparison

BILI vs PRAX Comparison

Compare BILI & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bilibili Inc.

BILI

Bilibili Inc.

HOLD

Current Price

$22.09

Market Cap

10.4B

Sector

Technology

ML Signal

HOLD

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$328.80

Market Cap

9.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BILI
PRAX
Founded
2009
2015
Country
China
United States
Employees
8088
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.4B
9.6B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
BILI
PRAX
Price
$22.09
$328.80
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
15
Target Price
$31.13
$572.13
AVG Volume (30 Days)
1.9M
345.4K
Earning Date
05-19-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$11.77
N/A
Revenue Next Year
$9.59
$7,758.26
P/E Ratio
$122.37
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.16
$34.89
52 Week High
$36.40
$354.87

Technical Indicators

Market Signals
Indicator
BILI
PRAX
Relative Strength Index (RSI) 34.98 53.49
Support Level $21.84 $282.49
Resistance Level $25.65 $353.83
Average True Range (ATR) 0.63 16.69
MACD 0.01 1.67
Stochastic Oscillator 6.44 55.97

Price Performance

Historical Comparison
BILI
PRAX

About BILI Bilibili Inc.

Bilibili is a Chinese online entertainment platform best known for its YouTube-like video-sharing service. Founded in 2009, it initially focused on long-form content centered around anime, comics, and gaming, or ACG, catering primarily to Generation Z users. Over time, the platform has expanded its content ecosystem to cover a broader range of interests, successfully attracting a more diverse audience beyond its original Gen Z base.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Share on Social Networks: